Article

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

University of Texas Southwestern Medical School, Dallas, TX, USA, .
Diabetologia (Impact Factor: 6.88). 08/2009; 52(9):1971-3. DOI: 10.1007/s00125-009-1452-2
Source: PubMed
Download full-text

Full-text

Available from: Julio Rosenstock, Mar 17, 2014
0 Followers
 · 
92 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine the prevalence of diabetes mellitus, glycemic control, and impact of diabetes on overall survival (OS) in an academic oncology practice.Methods: Data on cancer patients (1999-2008) were retrieved from the institutional cancer registry and linked to electronic files to obtain diabetes status and hemoglobin A1c (HbA1c) values within the first 6 months of cancer diagnosis. OS by cancer type with and without diabetes was compared using Cox regression.Results: Excluding skin and hematologic malignancies, 15,951 cancer cases were identified. Overall diabetes prevalence was 6.8% (n=1,090), declining over time (P<.001). Diabetes was common among patients with pancreatic (9.8% [61/624]), colorectal (7.7% [89/1,151]), or bladder cancers (7.6% [68/899]). Patients with diabetes were older (mean age, 70 vs 66 years; P<.001) and more likely to be male (66.3% [723/1,090] vs 60.2% [8,949/14,858]; P<.001). Mean HbA1c among diabetic cancer patients was 6.8% and did not differ across cancer types (P=.80). Only 58.6% (331/565) of diabetic cancer patients had all HbA1c <7.0% during the first 6 months following cancer diagnosis. Pancreatic cancer patients and coexisting diabetes had better OS than pancreatic cancer patients without diabetes (hazard ratio, 0.60; 95% CI 0.44-0.80; P<.001). Conversely, diabetic prostate cancer patients had worse OS than prostate cancer patients without diabetes (hazard ratio, 1.36; 95% CI 1.05-1.76; P=.02).Conclusion: In this academic oncology practice, diabetes was common, glycemic control often was suboptimal, and survival varied by cancer type. Additional study is needed to optimize glucose management and investigate mechanisms underlying age, sex, and survival differences.Abbreviations HbA1c, hemoglobin A1c OS, overall survival.
    Endocrine Practice 09/2012; 18(6):1-26. DOI:10.4158/EP12128.OR · 2.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucose-responsive polymer gels provide an attractive option for the design of a self-regulated insulin delivery system. Here, this paper reported the biocompatibility, glucose-sensitive behavior, and in vivo application of a dispersion of nanogels with three interpenetrating polymer networks of poly(N-isopropylacrylamide), dextran and poly(3-acrylamidophenylboronic acid) (P(NIPAM–Dex–PBA)). The nanogels had an average hydrodynamic radius of about 150 nm, and particle size increased with increasing content of dextran. The swelling behavior of the nanogels at different glucose concentrations revealed definite glucose sensitivity of P(NIPAM–Dex–PBA) particles. Furthermore, the analysis of relative cell proliferation suggested that the nanogels had good biocompatibility with L-929 mouse fibroblast cells. The loading amount of insulin, as a model drug, was up to 16.2%, and the drug release was dependent on the composition of dextran in the particles and the concentration of glucose present in release medium. In vivo experiments revealed that insulin-loaded nanogels decreased the blood glucose levels in diabetic rats and maintained 51% of the baseline level for almost 2 hours. The hypoglycemic effect of the drug-loaded nanogels was similar to that of free insulin after administration. Importantly, the drug-loaded nanogels could keep blood glucose levels stable and avoided blood sugar fluctuations compared with free insulin.
    Journal of Materials Chemistry 10/2012; 22(42):22788-22796. DOI:10.1039/C2JM34082H · 6.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus. Hyperinsulinemia is associated with increased cardiovascular risk, but the effects of exogenous insulin on cardiovascular disease progression have been less well studied. Insulin has been shown to have both cardioprotective and atherosclerosis-promoting effects in laboratory animal studies. Long-term clinical trials using insulin to attain improved diabetes control in younger type 1 and type 2 diabetes patients have shown improved cardiovascular outcomes. Shorter trials of intensive diabetes control with high insulin use in higher risk patients with type 2 diabetes have shown either no cardiovascular benefit or increased all cause and cardiovascular mortality. Glargine insulin is a basal insulin analog widely used to treat patients with type 1 and type 2 diabetes. This review focuses on the effects of glargine on cardiovascular outcomes. Glargine lowers triglycerides, leads to a modest weight gain, causes less hypoglycemia when compared with intermediate-acting insulin, and has a neutral effect on blood pressure. The Outcome Reduction With Initial Glargine Intervention (ORIGIN trial), a 6.2 year dedicated cardiovascular outcomes trial of glargine demonstrated no increased cardiovascular risk.
    Vascular Health and Risk Management 01/2015; 11:107-116. DOI:10.2147/VHRM.S50286